🇺🇸 FDA
Patent

US 9051249

Benzylamine derivatives as inhibitors of plasma kallikrein

granted A61KA61K38/00A61P

Quick answer

US patent 9051249 (Benzylamine derivatives as inhibitors of plasma kallikrein) held by KalVista Pharmaceuticals Limited expires Mon Jun 04 2035 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
KalVista Pharmaceuticals Limited
Grant date
Tue Jun 09 2015 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jun 04 2035 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
17
CPC classes
A61K, A61K38/00, A61P, A61P1/04, A61P1/18